Wells Fargo’s FibroBiologics FBLG Stock Holding History

Wells Fargo’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10	Closed	-$13	–	7645
2026 Q1	$13	Hold	10	–	–	﹤0.01%	6905
2025 Q4	$45	Hold	10	–	–	﹤0.01%	6541
2025 Q3	$109	Sell	10 -26	-72%	-$311	﹤0.01%	6377
2025 Q2	$451	Sell	36 -627	-95%	-$11.3K	﹤0.01%	6382
2025 Q1	$11.9K	Buy	663 +14	+2%	+$400	﹤0.01%	5855
2024 Q4	$26K	Buy	649 +211	+48%	+$11.3K	﹤0.01%	5693
2024 Q3	$27.1K	Buy	438 +21	+5%	+$1.4K	﹤0.01%	5555
2024 Q2	$41.7K	Buy	417 +407	+4,070%	+$77.6K	﹤0.01%	5360
2024 Q1	$2.16K	Buy	+10	New	+$2.4K	﹤0.01%	6022

Other funds holding FBLG

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo's FBLG Position: Q2 2026 in Review

Wells Fargo sold out of FibroBiologics (FBLG) in Q2 2026, closing a stake of 10 shares — an estimated $13 sold.

Wells Fargo first reported a position in FBLG in Q1 2024 and held it in 9 quarters. The position peaked at $41.7K in Q2 2024. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

Wells Fargo reported no remaining FibroBiologics position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 10 FibroBiologics shares in Q2 2026, an estimated $13.
Wells Fargo first reported a position in FibroBiologics in Q1 2024 and held it in 9 quarters.
Wells Fargo's FibroBiologics position peaked at $41.7K in Q2 2024.
16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.